BioMed Research International

Hereditary Tumours


Publishing date
08 Feb 2013
Status
Published
Submission deadline
21 Sep 2012

Lead Editor

1Department of Experimental and Clinical Medicine, The Magna Græcia University of Catanzaro, Italy

2Center for Medical Genetics, Ghent University Hospital, MRB, Belgium

3Department of Cell and Developmental Biology, Weill Cornell Medical College of Cornell University, New York, USA

4Dana-Farber Cancer Institute, Boston, USA

5Molecular Diagnostics Laboratory, NCSR Demokritos, Athens, Greece


Hereditary Tumours

Description

Germline mutations in critical high penetrance genes are responsible for cancer susceptibility, accounting for 5–10% of the incident tumours, which are therefore referred to as “hereditary tumours.” Individuals carrying inheritable mutations in these loci have a strongly increased risk of early onset neoplastic syndromes in several family members with a typical autosomal dominant pattern of inheritance. In some populations, specific mutant alleles recur with a higher carrier frequency because of a founder effect.

For several syndromes the causal genes have been identified. The most frequent syndromes include hereditary breast-ovarian cancer (HBOC), hereditary nonpolyposis colorectal cancer (Lynch syndrome), familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), neurofibromatosis type (NF1), and so forth. Examples of more rare syndromes are Li-Fraumeni syndrome, Cowden disease, von Hippel-Lindau syndrome, and so forth.

We invite investigators working in the field of familial cancer syndromes to contribute original research articles as well as review articles, which ideally should cover, whenever possible, the biological roles of the genes involved in cancer predisposition, tumor pathology, patient approach (genetic counseling and tools for risk assessment), technologies available for genetic analysis and early detection (automation and high-throughput sequencing), and novel therapeutic strategies (personalized medicine and gene-targeted therapies). Review articles should provide a comprehensive overview of the current knowledge, as well as outline the challenges and the open issues in the field. Potential topics include, but are not limited to:

  • HBOC, Lynch syndrome, FAP, MAP, and Li-Fraumeni syndrome
  • Studies aimed to further understanding the role of the cancer susceptibility genes in cell functions and organism development
  • Recently elucidated molecular pathways involved in tumorigenesis of familial cancer syndromes
  • Mutational analysis and population specific data
  • Results from novel analytical technologies
  • Genotype-phenotype correlations studies
  • Morphopathological correlations studies
  • Results emerging from animal models
  • Advances and future directions on the pathways to individualized approaches for the early detection, treatment, and prevention

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/ht/ according to the following timetable:

BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.